Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exisulind and Docetaxel in Advanced NSCLC
NCT00072618Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exisulind in non-small cell lung cancer (NSCLC), sponsored by Astellas Pharma. Primary endpoints: Safety and Tolerability and Efficacy. Started Oct 2001; status: completed.
02
Drugs
exisulind
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00072618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072618.